![Covadonga Pañeda](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : - $ au 31/03/2026
Covadonga Pañeda currently works at Altamira Therapeutics Ltd., as Chief Operating Officer from 2023.
Dr. Pañeda also formerly worked at LiMM Therapeutics SA, as Director-Development from 2020 to 2022 and Sylentis SA, as Manager-Research & Development from 2011 to 2018.
Dr. Pañeda received her doctorate degree from Universidad Autónoma de Madrid.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2025 | 0 ( -.--% ) | - $ | 31/03/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ALTAMIRA THERAPEUTICS LTD. | Directeur des opérations | 01/01/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
LiMM Therapeutics SA
 LiMM Therapeutics SA Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | 01/04/2022 |
Sylentis SA
 Sylentis SA BiotechnologyHealth Technology Operates as a biotechnology company that focuses on the development of new ophthalmic drugs and novel therapies based on RNAi technology | Directeur Technique/Scientifique/R&D | 01/06/2018 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Universidad Autónoma de Madrid
 Universidad Autónoma de Madrid Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sylentis SA
Sylentis SA BiotechnologyHealth Technology Operates as a biotechnology company that focuses on the development of new ophthalmic drugs and novel therapies based on RNAi technology | Health Technology |
Altamira Therapeutics Ltd.
 Altamira Therapeutics Ltd. BiotechnologyHealth Technology Develops RNA therapeutics for inner ear disorders | Health Technology |
LiMM Therapeutics SA
LiMM Therapeutics SA Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
